Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

Boehringer Ingelheim will collaborate with IBM (NYSE:IBM) to explore the use of blockchain technology in clinical trials, specifically to determine if blockchain can improve trial quality and patient safety at reduced cost via a decentralized framework enabling data integrity, provenance, transparency, patient empowerment and process automation.

Financial terms are not disclosed.

Selected tickers: XLV, XBI, PFE, MRK, BMY, NVS, TEVA, TAK, BHC, OTCQX:RHHBY, ABBV, AZN, GSK, BIIB, AMGN, GILD, LLY

Subscribe for full text news in your inbox